Peroxisome proliferator-activated receptor gamma coactivator 1a (PGC1a) is an accessory protein which can potentiate the transcriptional activation function of many nuclear hormone receptors. Its tissue distribution and physiological studies suggest that its principal in vivo roles are to promote cold-induced thermogenesis, mitochondrial biogenesis, hepatic gluconeogenesis, and fatty acid b-oxidation. It is expressed in the white adipose tissue of both humans and rodents, and in rodents it has been suggested to mediate in part the leptin-induced conversion of white adipocytes from fat storing to fat oxidising cells. In this study, quantitative real-time PCR has been used in human tissue to demonstrate that (1) PGC1a mRNA levels in subcutaneous fat are three-fold lower in morbidly obese than in slim subjects; (2) there are no differences in PGC1a mRNA between omental and subcutaneous mature adipocytes; (3) there is a robust induction of PGC1a expression during subcutaneous human preadipocyte differentiation ex vivo. Whether low PGC1a expression is a prelude to the development of obesity, or a consequence of that obesity, attempts to upregulate endogenous white adipose tissue expression may prove a valuable new avenue to explore in obesity therapy. Keywords: PGC1; white adipose tissue; preadipocyte; adipocyte; obesity Peroxisome proliferator-activated receptor gamma coactivator 1a (PGC1a) was first identified as a coactivator of PPARg in vitro, 1 although subsequent studies have revealed it to be promiscuous in such systems, able to coactivate PPARa, PPARd, the oestrogen receptor, thyroid hormone receptor, and hepatic nuclear factor 4a (HNF4a) among others. It is most highly expressed in brown adipose tissue, the heart and skeletal muscle, and has been shown to be upregulated during cold exposure in rodents. Further functional studies have elucidated its central role in coordinating adaptive thermogenesis through increased mitochondrial biogenesis and uncoupled oxidative metabolism. 2 More recently, initial rodent expression data were added to by the demonstration of a strong induction of PGC1a expression in the liver during fasting, when it has been shown to act in concert with the glucocorticoid receptor, CREB, and HNF4a to stimulate gluconeogenesis, 3,4 and with CREB and HNF4a to stimulate fatty acid oxidation. 5 Thus, altering PGC1a activity has emerged as a parsimonious strategy for influencing complex programmes of gene expression in response to external stimuli in a cell-and tissue-specific manner. PGC1a expression in white adipose tissue is low in both rodents and humans, where it is around 10% of that in liver. Although the small index study found relative suppression of PGC1a mRNA in the skeletal muscle of obese humans, no difference was found in WAT expression. 6 However, recent work in rodents has shown that hyperleptinaemia results in a dramatic decrease of white adipose tissue due to increased b oxidation, attributed to increased expression of PPARa and PGC1a. [7] [8] [9] Moreover, using a range of transgenic, pharmacological, and in vitro approaches, it has been shown not only that PPARd activation in white adipose tissue results in
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We have used real-time quantitative PCR to assess expression of PGC1a in human white adipose tissue and derived cells. The methods used have been described in detail previously. 11 In brief, adipose tissue samples were obtained from subjects undergoing elective laparotomy after at least 6 hours of fasting. For whole-fat analysis, RNA was extracted by homogenisation in RNA STAT-60 (AMS Biotechnology, Oxon, UK) with subsequent purification according to the manufacturer's instructions. For other studies, the tissue was subjected to collagenase digestion and cell fractionation according to standard protocols. 10 Mature adipocytes were collected and RNA was extracted immediately using the RNEasy mini extraction kit (Qiagen, West Sussex, UK). For differentiation studies, the stromovascular cell fraction, representing preadipocytes, was used. It was either plated and passaged four times before being grown to confluence, or plated at confluence as indicated, before being differentiated by the standard protocol described previously.
10
RNA was extracted from differentiating cells at defined time points using the RNEasy kit. For quantification, 100 ng of the total RNA was reverse transcribed in 20 ml reaction mixture, and 2 ml of the resulting first strand cDNA was subjected to real-time quantitative PCR on an ABI 7700 sequence detection system (Perkin-Elmer Biosystems). The oligonucleotide sequences used were as follows: PGC1a forward primer, 5 0 -GTG AAA TTG AGG AGT GCA CAG TAA A-3 0 ; PGC1a reverse primer, 5 0 -TCA CAG GTA TAA CGG TAG GTA ATG AAA-3 0 ; PGC1 probe, 5 0 FAM-TGC GGG ATG ATG GAG ACA GCT ATG G-TAMRA3 0 . All PGC1a values thus obtained were normalised to 18S rRNA levels from samples run in parallel (reagents supplied by Perkin-Elmer). Raw threshold cycle (C T ) values for PGC1a were around 28-29. Statistical analysis employed the Mann-Whitney U-test for unpaired samples and the paired Wilcoxon nonparametric test for paired samples.
The most striking finding was greater than three-fold suppression of PGC1a mRNA levels in the subcutaneous whole fat of morbidly obese subjects relative to lean controls (Figures 1a and 1b) . This is in contrast to the one previously published report, which compared patients with only mild obesity to lean controls 6 (mean BMI 31 kg/m 2 in the obese group in that study vs 52.3 kg/m 2 in the morbidly obese group in this). The same report, using competitive RT-PCR, also suggested that PGC1a expression was higher in visceral white adipose tissue than in subcutaneous tissue in the small number of patients studied. Our analysis of paired subcutaneous and omental mature adipocytes from nine patients failed to corroborate this ( Figure 1c ). When preadipocytes were subjected to differentiation conditions ex vivo, PGC1a expression in subcutaneous cells rose within 2 days to levels equivalent to those seen in mature adipocytes and whole fat ( PGC1a in human fat RK Semple et al data). This induction of expression was seen whether cells were passaged four times prior to differentiation (Figure 2a) or plated directly at confluence (Figure 2b ). Similar experiments with passaged omental stromovascular cells revealed basal PGC1a expression in omental cells to be some eightfold higher than that in cells from subcutaneous fat, but failed to demonstrate an increase in PGC1a expression during differentiation (data not shown). This may relate to the greater difficulty in obtaining pure omental preadipocytes ex vivo, due to heavy investment of visceral fat with blood vessels, and so before direct comparisons can be made between subcutaneous and omental preadipocytes, it will be necessary to assess the number of contaminating cells such as macrophages and endothelial cells in the omental stromovascular fraction. Our failure to show a difference between subcutaneous and omental mature adipocyte PGC1a expression supports the contention that the discordance in preadipocyte studies has a methodological basis.
Interestingly, addition of the specific and potent PPARg agonist rosiglitazone to the differentiation cocktail had no effect on the level of PGC1a expression in cells from either depot, despite its proven capacity to enhance differentiation ex vivo, and the suggestion from our previous studies that it may selectively enhance differentiation of subcutaneous preadipocytes. 12 Moreover, no relationship could be established between glycerol-3-phosphate dehydrogenase activity, a common surrogate marker of adipogenesis, and PGC1a expression (data not shown). All of this is consistent with the upregulation of PGC1a being an early event in preadipocyte differentiation beyond which there remain rate-limiting steps before acquisition of the fully differentiated phenotype, as evidenced by the demonstration that PGC1a expression is already induced 30-fold by 48 h of ex vivo differentiation (Figure 2b ). The expression studies described concentrate solely on PGC1a expression at the mRNA level, and before a definitive conclusion about its expression can be made, it will be necessary to confirm that PGC1a protein levels show the same pattern. This notwithstanding, our demonstration that PGC1a mRNA expression is suppressed in the whole fat of morbidly obese subjects is provocative. Although PPARg is the most abundant cognate nuclear hormone receptor in WAT, the expression pattern of PGC1a suggests it is more closely allied to pathways of mitochondrial biogenesis and fatty acid oxidation. In this regard, PPARa, expressed at low but defined levels in WAT, is a more likely target, while the almost ubiquitous PPARd has also recently been invoked as a physiologically relevant partner of PGC1a in white adipose tissue. 10 A central question is whether suppressed PGC1a expression is a predisposing factor for the accumulation of lipid in adipocytes through a constitutively lower rate of b oxidation, or whether it is a, possibly maladaptive, consequence of this accumulation. Genetic evidence suggests that PGC1a haplotypes and polymorphisms may indeed segregate with obesity 13 and insulin resistance, 14 while conversely, ectopic expression of PGC1a in WAT in rodents has been shown to change the adipocyte phenotype to that of a primarily oxidative cell. 1 Nevertheless, whether a cause or consequence of morbid obesity, the suggestion that PGC1a expression can be modulated with functional results in WAT is therapeutically tantalizing. This study is the first demonstration that PGC1a expression is induced during white adipocyte differentiation, and that this expression is suppressed in the white adipose tissue of morbidly obese subjects. Assuming the findings are replicated in larger groups, analysis of the molecular regulation of PGC1a expression in WAT will be important. The ultimate challenge will be to delineate a physiological regulatory pathway that modulates the energy-utilising phenotype of white adipocytes, and to develop ways to subvert this to the benefit of whole-body metabolism in a fat and calorie-rich environment. Obvious early steps to this end include assessment of the effect of hormones such as leptin and triiodothyronine on PGC1a expression, analysis of the PGC1a promoter and other regulatory sequences, and an extension of expression studies to PGC1b, a recently described homo- 
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RK Semple et al logue of PGC1a. 15 Particular attention should be paid to tissue-specific aspects of this regulation, in view of the deleterious results of constitutive PGC1a action in heart, where cardiomyopathy results, 16 and liver, where sustained gluconeogenesis may contribute to hyperglycaemia.
